Disorders of glycogen metabolism arise from inherited pathogenic variants in genes encoding enzymes or regulatory proteins essential to glycogen synthesis or degradation. The molecular basis differs across subtypes. Variants in GBE1 impair the glycogen branching enzyme, leading to accumulation of abnormally structured polyglucosan bodies in tissues. Variants in PYGM affect muscle glycogen phosphorylase, disrupting glycogen breakdown in skeletal muscle. PYGL encodes the hepatic isoform of glycogen phosphorylase, and its disruption preferentially affects hepatic glycogen mobilization. AGL encodes the glycogen debranching enzyme, and loss of its function impairs complete glycogen degradation. GYS1 encodes muscle glycogen synthase, linking it to glycogen synthesis defects. PFKM and PGAM2 affect glycolytic flux downstream of glycogen breakdown, while PGK1 encodes phosphoglycerate kinase involved in energy production. PRKAG2 encodes a regulatory subunit of AMP-activated protein kinase, with variants causing glycogen accumulation particularly in cardiac tissue. RBCK1 has been implicated in polyglucosan body myopathy. The inheritance patterns across these subtypes include autosomal recessive and X-linked modes, consistent with the diverse chromosomal locations of the implicated genes.

Diagnosis of glycogen metabolism disorders relies on a combination of clinical evaluation, biochemical testing, neuroimaging, histopathological analysis, and molecular genetic testing. In GBE1-APBD, suggestive clinical findings include onset at or after age 40 years, progressive neurogenic bladder, mixed upper and lower motor neuron signs producing spasticity and gait disturbance, and sensory loss in the distal lower extremities. Family history and ethnicity may provide additional diagnostic context. Neuroimaging findings contribute to the diagnostic assessment in neurologically affected subtypes. Tissue biopsy demonstrating characteristic polyglucosan bodies or abnormal glycogen deposits supports the diagnosis in relevant subtypes. Enzyme activity assays in blood cells, muscle, or liver tissue can confirm specific enzymatic deficiencies. Comprehensive molecular genetic testing identifying pathogenic variants in genes such as GBE1, PYGM, AGL, or other associated loci provides definitive genetic confirmation. Following initial diagnosis of GBE1-APBD, evaluation of the full extent of neurological, bladder, and autonomic involvement is undertaken to characterize individual disease burden. Surveillance over time includes neurological assessment for progression of upper and lower motor neuron signs, monitoring for emergence of new manifestations, urological evaluation of bladder function, and assessment for orthostatic hypotension.

Management of glycogen metabolism disorders is directed at the specific manifestations present in each affected individual. For GBE1-APBD, care is optimally provided through a multidisciplinary team encompassing specialists in physical medicine and rehabilitation, urology, and behavioral neurology or neuropsychology. Physical and rehabilitative interventions address gait difficulties, spasticity, and weakness arising from mixed motor neuron involvement. Urological management targets neurogenic bladder dysfunction. Autonomic dysfunction and orthostatic hypotension are addressed through appropriate supportive measures. For muscle-predominant subtypes, avoidance of precipitating triggers for myopathic episodes and supportive nutritional strategies may be relevant components of care. Cardiac manifestations in PRKAG2-related disease require cardiac-specific management approaches. The heterogeneity of this disorder group means that treatment plans are individualized based on the subtype diagnosed and the organ systems involved. Ongoing surveillance for disease progression guides adaptation of management strategies over time.

The prognosis in glycogen metabolism disorders is highly variable and dependent on the specific subtype, age of onset, and organs involved. Infantile-onset forms may follow a more severe course given the critical role of glycogen metabolism during early development and rapid growth. In GBE1-APBD, the progressive nature of the neurological manifestations, including worsening bladder dysfunction, gait impairment, and sensory loss, results in accumulating disability over time for most individuals. The involvement of both upper and lower motor neurons and the autonomic nervous system contributes to functional decline. Earlier age of symptom onset and the degree of neurological involvement at diagnosis may influence the rate of progression. For muscle-specific subtypes, prognosis is often more favorable with preservation of life expectancy in many cases, though exercise intolerance and episodic complications may affect quality of life. Cardiac-predominant subtypes carry prognosis heavily influenced by the degree of cardiac involvement. Multidisciplinary surveillance and symptomatic management can mitigate some functional consequences of disease progression across subtypes.

Research into glycogen metabolism disorders encompasses both basic science investigation of disease mechanisms and translational clinical trials. Eight active clinical trials are currently registered in this disease area, reflecting growing investigative interest. In the context of GBE1-APBD specifically, therapeutic investigations include the study of guaiacol and triacylglycerol mimetic 5 (TGM5) as candidate agents, with trials accessible through ClinicalTrials.gov in the United States and the EU Clinical Trials Register in Europe. These approaches aim to address the underlying metabolic or structural consequences of abnormal polyglucosan accumulation. Broader research efforts across the glycogen storage disease spectrum include enzyme replacement strategies, substrate reduction approaches, and gene-based therapeutic investigations targeting specific enzymatic deficiencies. The identification of the full spectrum of causative genes, including AGL, GBE1, GYS1, PFKM, PGAM2, PGK1, PRKAG2, PYGL, PYGM, and RBCK1, provides a molecular framework guiding both mechanistic studies and therapeutic target identification. Natural history studies and genotype-phenotype correlation analyses continue to refine the understanding of disease variability and inform the design of future interventional research.